Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population

American Health and Drug Benefits

Volumn 7, Issue 3, 2014, Pages 140-149

  Ray, Saurabh ^a   Bonafede, Machaon M ^b   Mohile, Nimish A ^c  

^a ABBOTT LABORATORIES   (United States)

^b IBM WATSON HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; CORTICOSTEROID; NARCOTIC ANALGESIC AGENT; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEATH; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEADACHE; HEALTH CARE COST; HUMAN; ICD-9-CM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; SEIZURE; UNITED STATES; YOUNG ADULT;

EID: 84902009182     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714-736.
2. Central Brain Tumor Registry of the United States. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. February 2011. www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf. Accessed March 15, 2014.
3. Stupp R, Mason WP, van den Bent MJ, et al; for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
4. Koshy M, Vilano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107:207-212.
5. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107:359-364.
6. Stupp R, Tonn JC, Brada M, Pentheroudakis G; for the ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v190-v193.
7. Lamers LM, Stupp R, van den Bent MJ, et al; for the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008;112:1337-1344.
8. Raborn ML, Pelletier EM, Smith DB, Reyes CM. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis. J Oncol Pract. 2012;8 (3 suppl):9s-15s.
9. Kutikova L, Bowman L, Chang S, et al. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol. 2007;81:61-65.
10. Porter KR, McCarthy BJ, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12:520-527.
11. Papagikos MA, Shaw EG, Stieber VW. Lessons learned from randomised clinical trials in adult low grade glioma. Lancet Oncol. 2005;6:240-244.
12. Abrey LE, Louis DN, Paleologos N, et al; for the Oligodendroglioma Study Group. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007;9:314-318.
13. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507. Erratum in: N Engl J Med. 2008;359:877.
14. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-350.
15. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
16. DeAngelis LM. Chemotherapy for brain tumors-a new beginning. N Engl J Med. 2005;352:1036-1038.
17. Fietkau R, Putz F, Lahmer G, et al. Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution. Strahlenther Onkol. 2013;189:993-995.
18. Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer. 1995; 76:1634-1642.
19. Wick W, Platten M, Meisner C, et al; for the NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707-715.
20. Malmström A, Grønberg BH, Marosi C, et al; for the Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916-926.
21. Gállego Pérez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29:3050-3055.